|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1101186502 |
| 003 |
OCoLC |
| 005 |
20231120010352.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
190515s2019 enk o 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d OPELS
|d N$T
|d EBLCP
|d UKMGB
|d OCLCF
|d YDX
|d UKAHL
|d OCLCQ
|d ERF
|d OCLCQ
|d OCLCO
|d COM
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBB996979
|2 bnb
|
| 016 |
7 |
|
|a 019408276
|2 Uk
|
| 019 |
|
|
|a 1101564734
|
| 020 |
|
|
|a 9780128135402
|q (electronic bk.)
|
| 020 |
|
|
|a 0128135409
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128135396
|q (print)
|
| 020 |
|
|
|z 0128135395
|
| 035 |
|
|
|a (OCoLC)1101186502
|z (OCoLC)1101564734
|
| 050 |
|
4 |
|a R853.B54
|
| 072 |
|
7 |
|a HEA
|x 012000
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 020000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 004000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 101000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 109000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 029000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 040000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 092000
|2 bisacsh
|
| 072 |
|
7 |
|a MMGT
|2 bicssc
|
| 082 |
0 |
4 |
|a 610.28
|2 23
|
| 245 |
0 |
0 |
|a Companion and complementary diagnostics :
|b from biomarker discovery to clinical implementation /
|c edited by Jan Tr�st J�rgensen.
|
| 264 |
|
1 |
|a London, United Kingdom :
|b Academic Press, an imprint of Elsevier,
|c 2019.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed May 15, 2019).
|
| 505 |
0 |
|
|a Front Cover; Companion and Complementary Diagnostics; Copyright Page; Contents; List of Contributors; Foreword; 1 An Introduction to Companion and Complementary Diagnostics; 1.1 Introduction; 1.2 History; 1.3 Companion Diagnostics; 1.4 Complementary Diagnostics; 1.5 Concluding Remarks; References; 2 The Drug-Diagnostic Codevelopment Model; 2.1 Introduction; 2.2 Assay Development and Analytical Verification; 2.3 Cutoff Selection; 2.4 Analytical Validation; 2.5 Clinical Validation; 2.6 Clinical Trial Designs; 2.7 Regulatory Requirements; 2.7.1 United States
|
| 505 |
8 |
|
|a 2.7.2 European Union and Other Countries2.8 The Impact of the Drug-Diagnostic Codevelopment Model; References; 3 Systems Biology in Biomarker Development for Cancer Signaling Therapy; 3.1 Introduction; 3.2 Systems Biomarker in Personalized Cancer Therapy; 3.3 Toward Systems Biomarker Development Through In Silico CDx Assay Model; 3.4 Systems Biomarker Identification in Signaling Control Interface; 3.5 Reprogramming of Signaling Networks as a Challenge in Systems Biomarker Identification in Cancer Therapy; 3.6 Systems Biomarker Identification by Exploring Contextual Genomic Features
|
| 505 |
8 |
|
|a 3.7 Machine-Learning Approaches in Systems Genomics and Pharmacology: Biomarker Identification Based on Omics Data3.8 Conclusion; Acknowledgments; References; 4 Immunohistochemistry; Abbreviations; 4.1 Introduction; 4.2 General Principles of Immunohistochemistry Assay Development; 4.2.1 A Note About Preanalytical Procedures; 4.2.2 Antibody Production and Selection; 4.2.2.1 Production of Monoclonal Antibodies; 4.2.2.2 Production of Polyclonal Antibodies; 4.2.2.3 Comparative Advantages of Monoclonal and Polyclonal Antibodies; 4.2.2.4 Host Animal Effects
|
| 505 |
8 |
|
|a 4.2.2.5 Professional Society Guidelines and Other Resources for Monoclonal Antibody Selection4.2.2.6 Primary Antibody Characterization; 4.2.3 Immunohistochemistry Assay Controls; 4.2.3.1 Tissue Controls; 4.2.3.2 Negative Reagent Controls; 4.2.4 Primary Antibody Titer; 4.2.5 Epitope Retrieval; 4.2.6 Detection Methods; 4.2.6.1 Detection Tags; 4.2.6.2 Direct and Indirect Detection; 4.2.6.3 Avidin-Biotin Detection Systems; 4.2.6.4 Streptavidin-Biotin Detection Systems; 4.2.6.5 Polymer- and Multimer-Based Detection Systems
|
| 505 |
8 |
|
|a 4.2.7 Verification and Validation of Immunohistochemistry In Vitro Diagnostics4.2.8 Risk Classifications for Immunohistochemistry In Vitro Diagnostics; 4.2.8.1 Class I; 4.2.8.2 Class II; 4.2.8.3 Class III; 4.3 Considerations Specific to Complementary and Companion Diagnostic Immunohistochemistry Assays; 4.3.1 Components of Complementary and Companion Diagnostic Immunohistochemistry Assay Systems; 4.3.2 Complementary and Companion Diagnostic Assay Development Challenges and Constraints; 4.3.2.1 Scoring Algorithms; 4.3.2.2 Selection of Primary Antibody Titer
|
| 650 |
|
0 |
|a Biochemical markers.
|
| 650 |
|
2 |
|a Biomarkers
|0 (DNLM)D015415
|
| 650 |
|
6 |
|a Marqueurs biologiques.
|0 (CaQQLa)201-0177920
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Holism.
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Reference.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Alternative Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Atlases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Essays.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Family & General Practice.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Holistic Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Osteopathy.
|2 bisacsh
|
| 650 |
|
7 |
|a Biochemical markers
|2 fast
|0 (OCoLC)fst00831950
|
| 700 |
1 |
|
|a J�rgensen, Jan Tr�st,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Companion and complementary diagnostics.
|d London, United Kingdom : Academic Press, an imprint of Elsevier, 2019
|z 0128135395
|z 9780128135396
|w (OCoLC)1053572058
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128135396
|z Texto completo
|
